CD302 and diabetic kidney disease: The downregulation of cd302 can increase insulin secretion and promote β cell survival, which makes it an attractive target for developing new medicine to treat type II diabetes and its complications (such as diabetes nephropathy) (Soni et al., 2013; Atanes et al., 2018; Tao et al., 2022).